These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 38752352)

  • 41. Pulmonary Vascular Distensibility Predicts Pulmonary Hypertension Severity, Exercise Capacity, and Survival in Heart Failure.
    Malhotra R; Dhakal BP; Eisman AS; Pappagianopoulos PP; Dress A; Weiner RB; Baggish AL; Semigran MJ; Lewis GD
    Circ Heart Fail; 2016 Jun; 9(6):. PubMed ID: 27301469
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Addition of sildenafil to bosentan monotherapy in pulmonary arterial hypertension.
    Mathai SC; Girgis RE; Fisher MR; Champion HC; Housten-Harris T; Zaiman A; Hassoun PM
    Eur Respir J; 2007 Mar; 29(3):469-75. PubMed ID: 17079256
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Inhaled sildenafil as an alternative to oral sildenafil in the treatment of pulmonary arterial hypertension (PAH).
    Rashid J; Patel B; Nozik-Grayck E; McMurtry IF; Stenmark KR; Ahsan F
    J Control Release; 2017 Mar; 250():96-106. PubMed ID: 28185800
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Sildenafil for the Treatment of Pulmonary Arterial Hypertension in Infants with Bronchopulmonary Dysplasia.
    Trottier-Boucher MN; Lapointe A; Malo J; Fournier A; Raboisson MJ; Martin B; Moussa A
    Pediatr Cardiol; 2015 Aug; 36(6):1255-60. PubMed ID: 25824807
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Risk-benefit considerations when prescribing phosphodiesterase-5 inhibitors in children.
    Magee AG; Makhecha S; Bentley S
    Expert Opin Drug Saf; 2015 May; 14(5):633-42. PubMed ID: 25746065
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Associations Between Sildenafil Use and Changes in Days of Hospitalization in a Population With Pulmonary Arterial Hypertension Associated With Connective Tissue Disease.
    Yang X; Sanders KN; Mardekian J; Mychaskiw MA; Thomas J
    Clin Ther; 2015 May; 37(5):1055-63. PubMed ID: 25818118
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The efficacy and safety of sildenafil in patients with pulmonary arterial hypertension associated with the different types of congenital heart disease.
    Zeng WJ; Lu XL; Xiong CM; Shan GL; Liu ZH; Ni XH; Gu Q; Zhao ZH; Li JJ; He JG;
    Clin Cardiol; 2011 Aug; 34(8):513-8. PubMed ID: 21678455
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Effect of Sildenafil Citrate on Pulmonary Arterial Systolic Pressure and Sub-maximal Exercise Capacity in Chronic Obstructive Pulmonary Disease.
    Shrestha SK; Srivastava B; Karki M; Khatri DB; Pradhan RM
    Kathmandu Univ Med J (KUMJ); 2017 Oct.-Dec.; 15(60):271-278. PubMed ID: 30580340
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Efficacy and safety of sildenafil treatment in pulmonary arterial hypertension: a systematic review.
    Wang RC; Jiang FM; Zheng QL; Li CT; Peng XY; He CY; Luo J; Liang ZA
    Respir Med; 2014 Mar; 108(3):531-7. PubMed ID: 24462476
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Cerebrovascular Effects of Sildenafil in Small Vessel Disease: The OxHARP Trial.
    Webb AJS; Birks JS; Feakins KA; Lawson A; Dawson J; Rothman AMK; Werring DJ; Llwyd O; Stewart CR; Thomas J
    Circ Res; 2024 Jul; 135(2):320-331. PubMed ID: 38832504
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Effect of phosphodiesterase-5 inhibition on exercise capacity and clinical status in heart failure with preserved ejection fraction: a randomized clinical trial.
    Redfield MM; Chen HH; Borlaug BA; Semigran MJ; Lee KL; Lewis G; LeWinter MM; Rouleau JL; Bull DA; Mann DL; Deswal A; Stevenson LW; Givertz MM; Ofili EO; O'Connor CM; Felker GM; Goldsmith SR; Bart BA; McNulty SE; Ibarra JC; Lin G; Oh JK; Patel MR; Kim RJ; Tracy RP; Velazquez EJ; Anstrom KJ; Hernandez AF; Mascette AM; Braunwald E;
    JAMA; 2013 Mar; 309(12):1268-77. PubMed ID: 23478662
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Comparison of the therapeutic and side effects of tadalafil and sildenafil in children and adolescents with pulmonary arterial hypertension.
    Sabri MR; Beheshtian E
    Pediatr Cardiol; 2014 Apr; 35(4):699-704. PubMed ID: 24253611
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Tadalafil: a long-acting phosphodiesterase-5 inhibitor for the treatment of pulmonary arterial hypertension.
    Arif SA; Poon H
    Clin Ther; 2011 Aug; 33(8):993-1004. PubMed ID: 21762988
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Safety and efficacy of transition from subcutaneous treprostinil to oral sildenafil in patients with pulmonary arterial hypertension.
    Keogh AM; Jabbour A; Weintraub R; Brown K; Hayward CS; Macdonald PS
    J Heart Lung Transplant; 2007 Nov; 26(11):1079-83. PubMed ID: 18022071
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Sildenafil therapy for pulmonary hypertension before and after pediatric congenital heart surgery.
    Palma G; Giordano R; Russolillo V; Cioffi S; Palumbo S; Mucerino M; Poli V; Vosa C
    Tex Heart Inst J; 2011; 38(3):238-42. PubMed ID: 21720460
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Phase 3 Trial of Sotatercept for Treatment of Pulmonary Arterial Hypertension.
    Hoeper MM; Badesch DB; Ghofrani HA; Gibbs JSR; Gomberg-Maitland M; McLaughlin VV; Preston IR; Souza R; Waxman AB; Grünig E; Kopeć G; Meyer G; Olsson KM; Rosenkranz S; Xu Y; Miller B; Fowler M; Butler J; Koglin J; de Oliveira Pena J; Humbert M;
    N Engl J Med; 2023 Apr; 388(16):1478-1490. PubMed ID: 36877098
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Prospective, open-label, uncontrolled pilot study to study safety and efficacy of sildenafil in systemic sclerosis-related pulmonary artery hypertension and cutaneous vascular complications.
    Kumar U; Sankalp G; Sreenivas V; Kaur S; Misra D
    Rheumatol Int; 2013 Apr; 33(4):1047-52. PubMed ID: 22833239
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Role of oral sildenafil in severe pulmonary arterial hypertension: clinical efficacy and dose response relationship.
    Garg N; Sharma MK; Sinha N
    Int J Cardiol; 2007 Sep; 120(3):306-13. PubMed ID: 17174417
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Impact of first-line sildenafil monotreatment for pulmonary arterial hypertension.
    Yanagisawa R; Kataoka M; Taguchi H; Kawakami T; Tamura Y; Fukuda K; Yoshino H; Satoh T
    Circ J; 2012; 76(5):1245-52. PubMed ID: 22333215
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Safety and long-term efficacy of transition from sildenafil to tadalafil due to side effects in patients with pulmonary arterial hypertension.
    Lichtblau M; Harzheim D; Ehlken N; Marra A; Pinado FP; Grünig E; Egenlauf B
    Lung; 2015 Feb; 193(1):105-12. PubMed ID: 25318865
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.